[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Part of paid clinical trials in Dallas, Texas.

Sponsor
Blue Earth Diagnostics
Study ID
NCT07432633
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • [18F]FPyQCP — DRUG
    positron emission tomography (PET)/computed tomography (CT) imaging

Study Details

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Key Dates

Start date
Mar 18, 2026
Status verified
Mar 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
71 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: [18F]FPyQCP PET/CT
    Each participant will receive \[18F\]FPyQCP followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2)

Primary Outcome Measure

Assess radiation dosimetry of [18F]FPyQCP (Cohort A) [ Time Frame: Up to 360 minutes post injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390
Steven Rowe, MD

Find similar trials in Dallas, TX

By condition
Colorectal cancerOvarian cancerGastric cancerPancreatic cancer
By specialty
OncologyGI oncologyGynecologic oncologyWomen's health
By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies